| ¿µ¹® | fibrin | ÇÑ±Û | ¼¶À¯¼Ò |
|---|---|---|---|
| ¼³¸í | Çǰ¡ ±»À» ¶§ ¼¶À¯¼Ò¿¡ Æ®·ÒºóÀÌ ÀÛ¿ëÇÏ¿© »ý±â´Â ¼¶À¯ °°Àº ´Ü¹éÁú. ¹«»öÀ̳ª ¿¯Àº Ȳ»öÀ» ¶í °íü·Î, ¹°¿¡ Àß ³ìÁö ¾ÊÀ¸¸ç Ç÷±¸¿Í ¾ûŰ¾î ÇǸ¦ ±»°Ô ÇÏ¿© ÃâÇ÷À» ±×Ä¡°Ô ÇÑ´Ù. |
||
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FbDP | fibrin degradation products |
| FDP | fibrin degradation product; fibrinogen degradation product; flexor digitorum profundus; frontodextra... |
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| FgDP | fibrinogen degradation products |
| FbDP | Fibrin Degradation Products |
|---|---|
| FDP | Fibrinogen-Fibrin Degradation Products |
| FDP | Fibrin Degradation Product |
| FDP | Fibrin(ogen) degradation product |
| FDP | Fibrin-fibrinogen degradation product |
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
|---|
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |
|---|---|
| degradation | <biochemistry, chemistry> The reduction of a chemical compound to one less complex, as by splitting off one or more groups. (18 Nov 1997) |
| edman degradation | A lab technique used to find out the order of amino acids in a polypeptide (chain of amino acids). It involves using the Edman reagent, phenyl isothiocyanate (PITC), to react one by one with each amino acid, in order. The technique is used in machines which automatically sequence (determine the order of subunits) polypeptides. (09 Oct 1997) |
| human fibrin foam | A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant. (05 Mar 2000) |
| fibrin | <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot. (12 Nov 1997) |
| fibrin calculus | A urinary calculus formed largely from fibrinogen in blood. (05 Mar 2000) |
| fibrin destabilase | <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin Pharmacological action: fibrinolytic agents Registry number: EC 3.4.99.- Synonym: destabilase (26 Jun 1999) |
| fibrin foam | <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods. Pharmacological action: haemostatics, tissue adhesives. (12 Dec 1998) |
| fibrinogen-fibrin conversion syndrome | <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma. (05 Mar 2000) |
| fibrin-stabilizing factor | <chemical> Fibrin stabilizing factor. It is a glycoprotein activated by thrombin in the presence of calcium to form factor xiiia. Factor xiii is found evenly distributed between plasma and platelets. Its function is to stabilise the formation of the fibrin polymer (clot) which culminates the coagulation cascade. Chemical name: Blood-coagulation factor XIII (12 Dec 1998) |
| fibrin thrombus | A thrombus formed by repeated deposits of fibrin from the circulating blood; it usually does not completely occlude the vessel. (05 Mar 2000) |
| fibrin tissue adhesive | <chemical> An autologous or commercial tissue adhesive containing fibrinogen and thrombin. The commercial product is a two component system from human plasma that contains more than fibrinogen and thrombin. The first component contains highly concentrated fibrinogen, factor viii, fibronectin, and traces of other plasma proteins. The second component contains thrombin, calcium chloride, and antifibrinolytic agent such as aprotinin. Mixing of the two components promotes clotting and the formation and cross-linking of fibrin. The tissue adhesive is used for tissue sealing, haemostasis, and wound healing. Pharmacological action: haemostatics, tissue adhesives. (12 Dec 1998) |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|